Bryan Stuart is the Chief Executive Officer and a director of Atavistik Bio, a Cambridge, Massachusetts biotechnology company building precision allosteric small molecule therapeutics on its Atavistik Metabolite-Protein Screening (AMPS) platform. He joined in July 2023 after more than two decades leading biopharma companies, including roles as CEO of Fulcrum Therapeutics, Yarra Therapeutics, and Kastle Therapeutics. Under his leadership Atavistik has raised a $120 million Series B in December 2025, later extended to $160 million, to advance its lead programs for hereditary hemorrhagic telangiectasia and myeloproliferative neoplasms toward the clinic.
Atavistik Bio is a Cambridge, Massachusetts clinical-stage biotechnology company that discovers precision allosteric small-molecule medicines. Its proprietary AMPS (Atavistik Metabolite-Protein Screening) platform, paired with an AI-enabled discovery engine, uses natural metabolites as bait to reveal hidden allosteric pockets on disease-driving proteins that conventional drug discovery cannot reach. The company is advancing an oral AKT1-selective inhibitor for hereditary hemorrhagic telangiectasia (HHT) and a JAK2 V617F mutant-selective program for myeloproliferative neoplasms (MPNs).
Diagonal Therapeutics is a Watertown, Massachusetts biotech building 'clustering antibodies' - multi-specific, agonist antibodies that bind two or more cell-surface receptors at once to switch broken signaling pathways back on. Its DIAGONAL Product Engine combines computational and experimental screening to sift billions of antibody combinations for the rare ones that restore receptor activity. The lead program, DIAG723, restores dysregulated ALK1 signaling to address the root cause of hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). Founded by Alex Lugovskoy with Atlas Venture, the company launched in 2024 with a $128M Series A and raised an oversubscribed $125M Series B in January 2026 to push DIAG723 into the clinic.
Alexey 'Alex' Lugovskoy is the co-founder and CEO of Diagonal Therapeutics, a Watertown/Cambridge, Massachusetts biotech building 'clustering' antibodies that switch cellular signaling back on rather than block it. A Harvard-trained biophysicist who left physics after deciding green leaves were more interesting than tau neutrinos, he spent two decades in antibody R&D at Biogen, Merrimack, Morphic, and Dragonfly before launching Diagonal in 2022. He has co-invented an FDA-approved cancer drug, authored more than 100 patents and papers, and edits the antibody journal mAbs. In January 2026 Diagonal closed an oversubscribed $125M Series B co-led by Sanofi Ventures and Janus Henderson to push its lead program, DIAG723, into human trials for hereditary hemorrhagic telangiectasia.